Alagille syndrome pathophysiology

Jump to navigation Jump to search

Alagille syndrome Microchapters

Home

Patient Info

Overview

Historical Perspective

Pathophysiology

Epidemiology & Demographics

Risk Factors

Causes

Differentiating Alagille syndrome from other Diseases

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alagille syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alagille syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alagille syndrome pathophysiology

CDC on Alagille syndrome pathophysiology

Alagille syndrome pathophysiology in the news

Blogs on Alagille syndrome pathophysiology

Directions to Hospitals Treating Alagille syndrome

Risk calculators and risk factors for Alagille syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Alagille syndrome is a multisystem genetic disorder that affects the liver, heart, eyes,face, skeleton, kidneys and vascular system.

Pathophysiology

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene is sufficient to cause the disorder. In some cases, an affected person inherits the mutation from one affected parent. Other cases may result from new mutations in the gene. These cases occur in people with no history of the disorder in their family.

Approximately 30-50% of individuals have an inherited mutation and about 50-70% have a de novo mutation. The parents of a child with a de novo mutation have increased risk for recurrence because of the possibility of germline mosaicism. The offspring of an individual with Alagille syndrome have a 50% chance of having Alagille syndrome.

Mutations in the JAG1 gene cause Alagille syndrome.[1] The JAG1 gene is involved in signaling between adjacent cells during embryonic development. This signaling influences how the cells are used to build body structures in the developing embryo. Mutations in JAG1 disrupt the signaling pathway, causing errors in development, especially of the heart, bile ducts in the liver, spinal column, and certain facial features.

NOTCH2 is also associated with Alagille syndrome.[2]

Narrowed and malformed bile ducts in the liver produce many of the health problems associated with Alagille syndrome. Bile is produced in the liver and moves through the bile ducts into the small intestine, where it helps to digest fat. In Alagille syndrome, the bile builds up in the liver and causes scarring that prevents the liver from working properly to eliminate wastes from the bloodstream.

Children with Alagille syndrome may be at risk for pathologic fractures, which manifest at an early age and in a unique distribution favoring the lower extremity long bones [3].

References

  1. Oda T, Elkahloun AG, Pike BL; et al. (1997). "Mutations in the human Jagged1 gene are responsible for Alagille syndrome". Nat. Genet. 16 (3): 235–42. doi:10.1038/ng0797-235. PMID 9207787.
  2. Samejima H, Torii C, Kosaki R; et al. (2007). "Screening for Alagille syndrome mutations in the JAG1 and NOTCH2 genes using denaturing high-performance liquid chromatography". Genet. Test. 11 (3): 216–27. doi:10.1089/gte.2006.0519. PMID 17949281.
  3. Bales CB, Kamath BM, Munoz PS, Nguyen A, Piccoli DA, Spinner NB; et al. (2010). "Pathologic lower extremity fractures in children with Alagille syndrome". J Pediatr Gastroenterol Nutr. 51 (1): 66–70. doi:10.1097/MPG.0b013e3181cb9629. PMC 2893241. PMID 20453673.

Template:WH Template:WS